Pipeline of GD & GBA-PD
This generated page lists source notes whose first nav_path entry is Pipeline of GD & GBA-PD. It is a coverage index, not a full synthesis page.
| source | nav path | headings |
|---|---|---|
| 20240722_181741 | Pipeline of GD & GBA-PD | Pipeline of GD & GBA-PD; NLRP3 PDE; 이주경; ADPD 2024; GCB PET / Lysosomotropic PET Notes; … |
| 20240722_181748 | Pipeline of GD & GBA-PD > Summary | Pipeline of GD & GBA-PD; Two Group Proportion Comparison; GBA-PD / sPD / HC Biomarker Matrix; Cognitive Readouts; Summary; … |
| 20240722_181752 | Pipeline of GD & GBA-PD > Summary | Pipeline of GD & GBA-PD; Eliglustat; Ambroxol; Mechanism; Preclinical Of Ambroxol; … |
| 20240722_181756 | Pipeline of GD & GBA-PD > Venglustat (Ibiglustat) | Pipeline of GD & GBA-PD; Ambroxol; Clinical Trials Of Ambroxol; Venglustat (Ibiglustat); Preclinical; … |
| 20240722_181800 | Pipeline of GD & GBA-PD > Prevail PR001 | Pipeline of GD & GBA-PD; Venglustat (Ibiglustat); Clinical Trials Of Venglustat; LEAP Biomarker Notes; MOVES-PD Biomarker And Clinical Results; … |
| 20240722_181805 | Pipeline of GD & GBA-PD > Prevail PR001 | Pipeline of GD & GBA-PD; Prevail PR001; Preclinical; PR001 Single-Dose Efficacy Study In The Genetic Mouse Model; Biodistribution And GCase Activity; … |
| 20240722_181809 | Pipeline of GD & GBA-PD > Prevail PR001 | Pipeline of GD & GBA-PD; PR001 Mouse Data: 4L/PS-NA Genetic Mouse Model; PR001 Mouse Data: A53T + CBE Model; Dose-Finding NHP ICM Biodistribution; Vector Genome Heatmap; … |
| 20240722_181813 | Pipeline of GD & GBA-PD > Summary | Pipeline of GD & GBA-PD; PR001A / PROPEL: Biomarker Goal And Interim Result; PR001A / PROVIDE; PR001A / PROGRESS; PR001A / PROCEED; … |
| 20240722_181818 | Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model | Pipeline of GD & GBA-PD; TAK-341 (MEDI1341); MEDI1341 Effector Function Note; MEDI1341 Affinity; Figure 4; … |
| 20240722_182123 | Pipeline of GD & GBA-PD > Summary | 총정리 GBA protein & activity POSTMORTEM (continued); Synapse; 총정리 GBA protein & activity POSTMORTEM] Activity: hetero only 에선 kurzawa가 유일.; PD only / PD+ heteroz / Hetero only / GD only / PD+GD matrix; Peripheral blood and GD studies; … |
| 20240722_182126 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | 총정리 GBA protein & activity (continued); Uncertain Spans |
| 20240722_182130 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | 총정리 GBA protein & activity (continued); Uncertain Spans |
| 20240722_182133 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | 총정리 GBA protein & activity (continued); Uncertain Spans |
| 20240722_182136 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity, GlcCer, GlcSph | Marker priority, 202107 Comp lysosomal target dashboard, and Summary GBA protein & activity, GlcCer, GlcSph; Marker priority; 202107 Comp lysosomal target dashboard; Summary GBA protein & activity, GlcCer, GlcSph; Uncertain Spans |
| 20240722_182139 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity | Summary GBA protein & activity (continued), Summary table: GBA-PD patients, and Read the Paper (A) GBA Pathway Biomarkers; Summary table: GBA-PD patients; Read the Paper (A) (GBA Pathway Biomarkers for Genetic and Idiopathic PD); Uncertain Spans |
| 20240722_182143 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Read the Paper | Read the Paper (>) GBA Pathway Biomarkers for Genetic and Idiopathic PD; Stratification by GBA pathway; 총정리중 GBA+PD에서 Lysosomal 반; S: Lysosome Lysosomal autophagy POSTMORTEM; Lysosomal autophagy model rows; … |
| 20240722_182146 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity | 총정리 GBA protein & activity (continued), Sidransky 2012 review, Saposin C summary; [Gegg 2012] GBA activity / protein level; Table Below by Sidransky 2012 review; Saposin C summary; Lower Saposin / GBA table; … |
| 20240722_182149 | Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > a-syn POSTMORTEM | a-syn POSTMORTEM, a-syn SH-SY5Y + Cullen, a-syn PC only, FRACTIONATION; Choi 2011 요약; Postmortem rows (Mazzulli 2011, Murphy 2013, Murphy 2014); a-syn SH-SY5Y + Cullen: probably this is all for cell line]; a-syn PC only; … |
| 20240722_182153 | Pipeline of GD & GBA-PD > Summary > GBA | Sidransky 2012 review (continued), PD-GD / GBA1-PD notes, GBA gene, GBA Mutation detection method; Sidransky 2012 review table continuation; PD-GD / GBA1-PD notes; GBA; GBA Mutation detection method; … |
| 20240722_182157 | Pipeline of GD & GBA-PD > GBA > Structure of GBA protein | Carrier screening (continued), Structure / Function / Turnover / Expression / Lifecycle of GBA, activity (‘BGL test’); Carrier screening (continued); Structure of GBA protein (EC 3.2.1.45); Function of GBA protein; Turnorver of GBA protein; … |
| 20240722_182200 | Pipeline of GD & GBA-PD > GBA > GBA activity (BGL test) | GBA activity (‘BGL test’); Product (kit); Uncertain Spans |
| 20240722_182203 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway | Sebastian table tail, Product (kit), Patient selection, Catalytic pathway, GSL flux, GluCer / GalCer isoforms, Gangliosides; Sebastian 20201124 (continued); Product (kit); Catalytic pathway; GluCer (Glucosylceramide) isoforms; … |
| 20240722_182207 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides | GluCer / GalCer isoforms (continued), Gangliosides, Sphingolipid pathway; GlcCer (Glucosylceramide); Gangliosides; Salvage pathway / Degradation; Sphingolipid base structure; … |
| 20240722_182210 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides | Gangliosides Synthesis / Salvage / Degradation, Sphingolipid base, Disease cascade, Glycolipid metabolism, GBA chaperone; Gangliosides table (continuing from previous capture); Salvage pathway / Degradation; Sphingolipid base structure; Ganglioside / sphingolipid degradation cascade (figure labels); … |
| 20240722_182213 | Pipeline of GD & GBA-PD > GBA > Catalytic pathway > Gangliosides > GlcSph | Disease cascade tail, Glycolipid metabolism, GBA1 / GlcSph cycle, GBA chaperone / GCS inhibitor, GlcSph section; Ganglioside / sphingolipid degradation cascade tail (figure labels); 위 그림에서 cerebroside 는 = GlcCer, GalCer; Glycolipid metabolism schematic; GBA1 / GlcSph cycle inset; … |
| 20240722_182216 | Pipeline of GD & GBA-PD > GD > Mutations Summary | GlcSph (continued) / GD: Dx, Epidemiology, Mutations Summary, mutation distribution; GD; Dx of GD; Epidemiology of GD (prevalence); Mutations Summary; … |
| 20240722_182219 | Pipeline of GD & GBA-PD > GD > Types and Neuropathology | Pathophysiology In GD, GBA1 mutations, Event / Observational markers, Types and Neuropathology; Pathophysiology In GD; Types and Neuropathology; Uncertain Spans |
| 20240722_182224 | Pipeline of GD & GBA-PD > GD > Parameters > GD 1 Summary | Type 3 / GD3 (continued), CNS Sx in GD3, Parameters / GD 1 Summary; Type 3 (continued); Type 3 + PD; CNS Sx in GD3; Parameters / GD 1 Summary; … |
| 20240722_182227 | Pipeline of GD & GBA-PD > GD > Parameters > GD 3 Summary | GD 1 Summary tail, GD 3 Summary, GlcCer / GlcSph (detail), Narita 2016 patient table; GD 1 Summary (continued); SRT response (Smid 2016 #529); 2019 Lukina (Eliglustat); GD 3 Summary; … |
| 20240722_182230 | Pipeline of GD & GBA-PD > GD > Parameters > GD 3 Summary | Narita 2016 patient body, Plasma in GD 1, Reference values, Animal models of GD; Narita 2016 #560 (continued); Plasma in GD 1; Experimental; Tottori univ / Dried blood spot in GD 3; … |
| 20240722_182233 | Pipeline of GD & GBA-PD > GD > Animal models of GD | 2019 Lukina (re-shown), Animal models of GD (continued), hGBA-L444P-tg8 mouse, GCB Mouse Model Substrate Comparison; 2019 Lukina Eliglustat (re-shown); Animal models of GD (continued); hGBA-L444P-tg8 figures and notes; GCB Mouse Model Substrate Comparison; … |
| 20240722_182237 | Pipeline of GD & GBA-PD > GD > Animal models of GD | D409V/D409V KI, GBA enzyme assay, conditional / nGD models, animal models comparison, Saposin C dose; D409V/D409V KI; GBA enzyme assay; MJFF: GBA D409VKi (hom) and crossed them with thy-1 aSyn or introduced PFF; nGD model / conditional; … |
| 20240722_182241 | Pipeline of GD & GBA-PD > GD > Animal models of GD > Outcome measure in nGD | Stephens 1978 (continued), animal model literature rows, Outcome measure in nGD (SST / mSST); Stephens 1978 (continued); Animal model literature rows; Outcome measure in nGD; mSST domain scoring; … |
| 20240722_182245 | Pipeline of GD & GBA-PD > GD > Parameters > Oculomotor measurements | Outcome measure (continued), Sample size in nGD, Oculomotor measurements, Saccade & PLR, Retina in nGD; Outcome measure (continued); Sample size estimation in nGD; Oculomotor measurements; Photoreceptors (in retina겠지); … |
| 20240722_182248 | Pipeline of GD & GBA-PD > GD > Parameters > Retina in nGD | Hopf saccadometry tail, Retina in nGD / Retina & LSD, PLR / chromatic pupillometry, ERG, CRO / KOL, Lipofuscin; Hopf saccadometry (continued); Retina in nGD; Retina & LSD; PLR / chromatic pupillometry; … |
| 20240722_182252 | Pipeline of GD & GBA-PD > GD > Parameters > Oculomotor measurements | RGC, Retinal PK, Short ciliary nerves, Antiepileptic drugs / retinal layers, RGC table, Study plan; RGC; Retinal PK; Short ciliary nerves; The effect of antiepileptic drugs on visual performance; … |
| 20240722_182255 | Pipeline of GD & GBA-PD > GBA-PD > Mutation GBA-PD | 2021 WORLDSymposium Ayuko Iverson, Narita Aya, Handover to Otake, GBA-PD penetrance, Mutation GBA-PD; 2021 WORLDSymposium Ayuko Iverson; Narita Aya (Iottori / Tottori univ); Handover to Otake on GD; GBA-PD / Penetrance (LIFETIME); … |
| 20240722_182259 | Pipeline of GD & GBA-PD > GBA-PD > MOA GBA-PD | Postmortem tail, Odds ratios, Phenotype / Cognition GBA-PD, Gene Dose Effect, MOA GBA-PD; Postmortem GBA-PD (continued); Odds ratios; Phenotype of GBA-PD; Cognition GBA-PD; … |
| 20240722_182303 | Pipeline of GD & GBA-PD > GBA-PD > Motor vs Cognition | aSyn spreading tail, ER stress, OS, Inflammation, Motor vs Cognition, Cognition / Dementia; aSyn spreading (continued); ER stress; OS; Inflammation; … |
| 20240722_182306 | Pipeline of GD & GBA-PD > GBA-PD > Animal models of GBA-PD | In vitro GBA-PD tail, 20191125 TAK Okai matrix, 20201209_ACi overview, Animal models of GBA-PD start; In vitro GBA-PD (continued); Below from 20191125 TAK Okai san slide gba-gt slide; Below from 20201209_ACi overview; Animal models of GBA-PD (start) |
| 20240722_182310 | Pipeline of GD & GBA-PD > GBA-PD > Correction studies | Animal models of GBA-PD tail, Correction studies (Rocha 2015 / AAV-A53T / Rockenstein 2016), S15 model, Sardi 2018 start; Animal models of GBA-PD (continued, A53T α-syn row); Correction studies; S15 model comparison; Sardi et al. 2018, PMID ?; … |
| 20240722_182313 | Pipeline of GD & GBA-PD > GBA-PD > Correction studies | Correction studies tail, Message 모음 (GBA activity / GlcCer / GlcSph / a-syn), Goals, w reduced GBA activity Gene Therapy; Correction studies (continued); Message 모음 (GBA activity-GlcCer GlcSph - a-syn); SNCA/SNCA; CBE mice / PR001; … |
| 20240722_182316 | Pipeline of GD & GBA-PD > GBA-PD > GBA vs UPDRS vs MOCA | Patient Selection, nGD biomarker grid, Models / Omics, BMx Milestones, Patient recruitment, GBA vs UPDRS vs MOCA; Patient Selection; nGD biomarker / study-design grid; Model; Omics / Imaging / Neurophysiologic / CSF proteomics; … |
| 20240722_182320 | Pipeline of GD & GBA-PD > GBA-PD > GBA vs UPDRS vs MOCA | GBA vs UPDRS vs MOCA (full literature comparison); Top longitudinal block (continued); Uncertain Spans; Clinical dev Scenarios; genotype / Activity / Activity-DBS rows; … |
| 20240722_182323 | Pipeline of GD & GBA-PD > GBA-PD > GBA vs UPDRS vs MOCA | Cognition / Motor+cog / NfL tail, Progression summary, MRI GBA, Leocadi 2022, Thaler 2018, Agosta 2013; Progression summary; MRI GBA; longitudinal PPMI (Caminiti, 2022 #2706); MRI; … |
| 20240722_182326 | Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA | MRI GBA tail (Caminiti DATSCAN / Leocadi / Thaler / Agosta / Filippi), PET Imaging GBA progress; MRI GBA (continued); DATSCAN longitudinal text; Leocadi 2022 #2708 (Italy); Cortical thickness and Sub-cortical Volume; … |
| 20240722_182330 | Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA | PET Imaging GBA history, Handover to Otake, Catalytic vs Allosteric binders, PET SC, GBA GT reporter table; Cf) Functional assay; History (Takeshi Wakabayashi / Otake / Makoto Fushimi); Handover to Otake-san on GBA PET; 1. History; … |
| 20240722_182333 | Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA > GBA Activator | AADC PET tail, Rationale of GBA PET, GBA expression evaluation, DDU/MJFF PET Imaging GBA, GBA Activator PRC1; AADC PET tail; Rationale of GBA PET; GBA expression evaluation by imaging; DDU’s PET Imaging GBA; … |
| 20240722_182336 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > RD-DDU GBA Activator | GBA Activator criteria, Target profiles, Definition, GBA activity / GlcSph, RD-DDU GBA Activator, L444P Lyso-GL1, GBA GT start; GBA Activator criteria (continued); 20200428 Ceri meeting — Target profiles to meet the milestones (nGD); Definition (Below 20200529 LGE sDIB); GBA activity and GlcSph reduction; … |
| 20240722_182339 | Pipeline of GD & GBA-PD > GBA-PD > GBA GT > Executive summary | GBA GT Executive summary cassette selection, 3m-mice ICV screen, D409V 7-group selection, TE / PRC1 / Bettina, PD mouse model 4L/PS; STIG1 — cassette selection (criterion: GBA transgene expression ≥ 1× endogenous GBA); 3m mice ICV experiment (3 groups); 7-group D409V homozygous cassette-selection study (rAAV9, ICV); MOI definition; … |
| 20240722_182343 | Pipeline of GD & GBA-PD > GBA-PD > GBA GT > NHP studies > SNBR (Shin Nippon Biomedical Laboratories) | In vitro GBA-PD POC, GBA-GT PK-PD strategy, Immunogenicity assays, NHP studies / SNBR; In vitro GBA-PD model (continued); GBA-GT [PK-PD strategy]; GBA GT [Immunogenicity assays] prc1; NHP studies; … |
| 20240722_182346 | Pipeline of GD & GBA-PD > GBA-PD > GBA GT > TM GT GBA-PD | SNBR/NHP tail, Otake-san’s update, RD-DDU GBA GT, TM GT GBA-PD planning matrix, GBA PET / mRNA / pathway; SNBR / NHP results (continued); Otake-san’s update; RD-DDU GBA GT; TM GT GBA-PD; … |
| 20240722_182351 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > NHP Translational Model | Sample size estimation, Tx Paradigm, Biomarker Usage Map, DMPK PK/PD, Translational questions, Tempo code 43/6-100; Top header carry-over; Experimental Medicine; Tx Paradigm; Biomarker Usage Map: GBA activator in PD (Takeda); … |
| 20240722_182355 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor | GCB-BTV Executive summary tempo code, Biodistribution Studies, Comp Bio E-selectin, Competitor (Roche / BIAL LTI-291 / NCT05819359 ACTIVATE); GCB BTV Executive summary: tempo code 43/6-100; Biodistribution Studies; Comp Bio; Competitor; … |
| 20240722_182358 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor > Fusion Protein | BIAL LTI-291-004 tail, GBA activation table, Questions to BIAL, Gain Therapeutics GT-02287, Fusion Protein anti-TfR1 sdAbs; BIAL LTI-291-004; GBA activation table; Questions to BIAL; Gain Therapeutics GT-02287; … |
| 20240722_182402 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > RD DDU’s PET Imaging GBA | RD DDU’s PET Imaging GBA: GCB PET vs Lysosomotropic PET, BD study, Pharmacological modulation, Sample size estimation; PE1; GCB PET vs Lysosomotropic PET; Feasibility / BD study / Pharmacological modulation study; Sharefoldr / team meeting / 001 PE preparation; … |
| 20240722_182406 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Acid ceramidase inhibitor | IVC / TM / GBA2, Acid ceramidase inhibitor Yuta exec summary, Acid ceramidase / Farber lipogranulomatosis genetics; GBA2; Model system; Acid Ceramidase inhibitor — Executive summary (Yuta) (PFR-4153-100); Questions / Research hypothesis; … |
| 20240722_182409 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GALC (galactosylceramidase) > Genetics GALC for PD | Farber lipogranulomatosis (continued), IPDGC ASAH1 LSD variants table, CADD C-Score note, GALC, Genetics GALC for PD; Farber lipogranulomatosis (continued); IPDGC LSD-Gene-Variants Supplementary Table 3 (ASAH1); Cf) CADD C-Score; GALC (galactosylceramidase) (=galactocerebrosidase) (=Galcase); … |
| 20240722_182412 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GalactosylSph (=psychosine) > Assay of GalactosylSph | GALC Genetics tail (NIH ClinVar tally), GalactosylSph (=psychosine, GalSph), Assay of GalactosylSph, Krabbe’s Disease start; NIH ClinVar Variation type / Clinical significance (GALC tail); Galactosylsph (=psychosine, GalSph); Disease state comparison; aSyn / Krabbe relationship; … |
| 20240722_182416 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Pipeline of KD > Target validation and correction | Krabbe psychosine continued, KD subtypes, Pipeline of KD, MOA for PD, Monthly Report (AC Inhibitor), Safety / Target validation; Krabbe psychosine continued; Pipeline of KD; MOA for PD; Monthly Report (AC Inhibitor) 202101; … |
| 20240722_182419 | Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Target validation and correction > 총정리중 GBA+PD에서 Lys | Safety BM tail, Kim 2018 carmofur GBA-KO results, Figure 7 / Figure 8, GalSph / psychosine summary, Krabbe questions, GALC enzyme summary; Safety BM tail; Target validation and correction — Kim 2018 #1185 carmofur GBA-KO; GalSph (psychosine) summary; Krabbe / open questions; … |
| 20240722_182422 | Pipeline of GD & GBA-PD > Supplement > CNS & PNS > Cerebral Cortex | AIM-PD-AD Emory study, Anatomy CNS & PNS, Classification of nervous system, Spinal nerve, Cerebral Cortex layers; AIM-PD-AD (Emory University); Preliminary Results [from 제목있는 문서]; [Plan]; Anatomy — CNS & PNS; … |
| 20240722_182426 | Pipeline of GD & GBA-PD > Supplement > Cerebral Cortex > Neuron > Synapse | PNS / Spinal nerve / Cerebral Cortex (continued), Neuron / Synapse / Dendritic spines / PD-related changes; PNS / Somatic / Autonomic; Classification of nervous system; Spinal nerve; Cerebral Cortex (6 layers); … |
| 20240722_182429 | Pipeline of GD & GBA-PD > Supplement > Neuron > Synapse > Postsynaptic density > Cranial nerve | Neuron / Synapse continued, Asymmetric synapse density table, turnover, Synapse Asymmetric vs Symmetric, Postsynaptic density, Cranial nerve; Neuron; Common types of dendritic spines; Asymmetric synapse density; turnover; … |
| 20240722_182433 | Pipeline of GD & GBA-PD > Supplement > Cranial nerve > Facial n > Nigrostriatal pathway > Basal Ganglia | Cranial nerves nuclei tail, Facial n decomposition, Nigrostriatal pathway, Wakabayashi 2006 postmortem, SNc / DA neurons, Functional subdivisions of striatum, Basal Ganglia start; Cranial nerves nuclei tail; Facial n; Nigrostriatal pathway; Wakabayashi 2006 postmortem (paranigral nucleus PN, medial group MG, dorsal group DG, ventrolateral part VL); … |
| 20240722_182436 | Pipeline of GD & GBA-PD > Supplement > Basal Ganglia > MBN (nucleus basalis of M…) > Development of brain (bra…) > Brainstem | Basal Ganglia tail, Substantia nigra MR sequences, MBN (nucleus basalis of Meynert), Development of brain, Brainstem (Pons / LDT / Locus coeruleus / Medulla), Borghammer 2021 BODY-FIRST vs BRAIN-FIRST PD; Substantia nigra MR sequences; MBN (nucleus basalis of Meynert); Development of brain (brain vesicles); Brainstem; … |
| 20240722_182440 | Pipeline of GD & GBA-PD > Supplement > Gut > Commissures > Anatomy-Neurological signs > General | (Borghammer, 2021 #1484) BODY-FIRST vs BRAIN-FIRST PD, Commissures, Anatomy-Neurological signs / General, motor anatomy table, Reported signs and symptoms; (Borghammer, 2021 #1484); Panel A — Connection diagram; Panel B — Brain first; Panel C — Body first; … |
| 20240722_182443 | Pipeline of GD & GBA-PD > Supplement > PD > Animal model > CROs > Database > Antibody > Epitope mapping | PD neurological signs (motor + non-motor), Animal model / CROs / Database, Antibody monoclonal vs polyclonal, Epitope mapping, Affinity Maturation, APOE start; PD — Neurological signs; Animal model; CROs; Database; … |
| 20240722_182447 | Pipeline of GD & GBA-PD > Supplement > Antibody > Epitope mapping > APOE > AQP4 potentiator | AQP4 potentiator (mislocalization / amyloid / p-tau), Glymphatic system in PD, AQP4 SNP, Burfeind 2017 cohort, Target validation, Ariba procurement, Astrocyte start; AQP4 potentiator; Increased amyloid accumulation in AQP4 KO × APP-PS1 mice (Mol Neurodegener. 2015, 10:58); Exacerbation of p-tau accumulation and neuronal death in AQP4 KO × PS19 mice; Glymphatic system in PD; … |
| 20240722_182451 | Pipeline of GD & GBA-PD > Supplement > PET for astrocyte > aSyn > Animal models of aSyn > Non-Spreading Models | Reactive astrocytes A1/A2, (Li, 2019 #2281) molecular-expression table, PD and astrocyte, PET for astrocyte [11C]BU99008, aSyn animal models Non-Spreading + PD mouse models in QPS Line 61; Reactive astrocytes (small summary); Reactive astrocytes — Below (Li, 2019 #2281); PD and astrocyte; PET for astrocyte; … |
| 20240722_182454 | Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Non-Spreading Models > Spreading Models | Non-Spreading Models continued (WT Wade-Martins / F28tg / mjff / Mutant M83 PrP / KI rat / Truncated), Spreading Models, in vivo evidence, Atuka NHP results matrix; Animal models of aSyn — Non-Spreading Models (continued); Spreading Models; Methods; in vivo evidence; … |
| 20240722_182457 | Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Spreading Models | Atuka NHP Results matrix tail, Woodruff lab a-syn of mouse, PFF model (mouse pre-formed α-synuclein fibril), TAKEDA w Atuka Lentivirus, Gordon 2018 #587 / Chu 2019 / Luk 2012 / Duffy 2018 / Patterson 2019; Atuka NHP Results matrix (continued); Woodruff lab; PFF model (mouse, pre-formed α-synuclein fibril); Spreading models — TAKEDA w Atuka and key references |
| 20240722_182501 | Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Non-Spreading Models > Spreading Models | Patterson 2019 / SNCA BAC tg mouse / Bru 2013 #1370 row tail, spreading-models comparison table (PFF vs AAV with mechanism / Tx aims / Chung 2019 paragraph), Rey 2019 / 2018 / 2016 olfactory-bulb PFF rows, PFF preparation start; Spreading-models row continuation (PFF + AAV characterization); Olfactory-bulb PFF rows; PFF preparation |
| 20240722_182504 | Pipeline of GD & GBA-PD > Supplement > Non-Spreading Models > Spreading Models > Summary of a-syn animal models > MOA of aSyn spreading | PFF preparation tail (storage / sonication / pilot validation), Vargas 2019 Summary of a-syn animal models Table 1, Transgenic vs Vector vs Injection matrix, MOA of aSyn spreading axon transport table, Antibodies to aSyn start; PFF preparation (continued); Summary of a-syn animal models (J.Y. Vargas et al., Ageing Research Reviews 50 (2019) 89-101); Table 1 — Summary of in vivo studies representing the major milestones in the understanding of α-syn prion-like spreading properties.; Transgenic vs Vector-mediated α-syn vs Injection comparison; … |
| 20240722_182507 | Pipeline of GD & GBA-PD > Supplement > Summary of a-syn animal models > MOA of aSyn spreading > Antibodies to aSyn > Astrocytic aSyn | MOA of aSyn spreading tail, Antibodies to aSyn (matrix + per-antibody host/Species/epitope), Vaikath 2019 #1599 antibody fragment map, Astrocytic aSyn (Aflaki 2020 GD1/GD2 iAstrocytes), CSF & Blood Total aSyn level start; Antibodies to aSyn; Per-antibody host / Species / epitope; Astrocytic aSyn; CSF & Blood (a-syn) |
| 20240722_182510 | Pipeline of GD & GBA-PD > Supplement > MOA of aSyn spreading > Antibodies to aSyn > Astrocytic aSyn > CSF & Blood (a-syn) | CSF & Blood (a-syn) — total aSyn levels, Why reduced in CSF? paragraph, King 2022 / Eusebi 2017 / Chou 2014 / Mollenhauer 2017 / Hall 2016 / Hansson 2014 / Compta 2015 / Majbour 2021 DenoPa / van Steenoven 2018 VUMC studies; Why reduced in CSF?; Total aSyn level — study comparison; Uncertain Spans |
| 20240722_182514 | Pipeline of GD & GBA-PD > Supplement > Astrocytic aSyn > CSF & Blood (a-syn) > Distribution > Expression of aSyn | CSF & Blood (a-syn) study rows continued (Schirinzi 2019 / Wang 2012 / PD01A / Lin 2019 / Chang 2019 / Wang 2020 / Chatterjee 2020 / Yamashita 2023 / Transpharmation Attyloid Blömeke 2022), Js summary table, MDS 2020 PD01A note, Distribution, Expression of aSyn, Bulk tissue SNCA violin plot, Postmortem brain study rows; CSF & Blood (a-syn) — study rows continued; Summary; Distribution; Expression of aSyn; … |
| 20240722_182518 | Pipeline of GD & GBA-PD > Supplement > Function (of normal aSyn) > Grading/Scoring of LB pathology > Homology > In vitro studies of aSyn | Function (of normal aSyn), Grading/Scoring of LB pathology, Homology, In vitro studies of aSyn matrix, In vitro pharmacology assays; Function (of normal aSyn); Grading/Scoring of LB pathology; Homology; In vitro studies of aSyn; … |
| 20240722_182522 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aS… > Oligodendrocytic aSyn > PET aSyn | Lewy Body / components / Two types / Toxic mechanisms / Lewy neurites, Lipid-aSyn interaction review, Mutations SNCA, Neurodegeneration and aSyn (Mori 2006 + Lee 2017 staging table), DBM, Oligodendrocytic aSyn, PET aSyn vendor matrix start; Lewy Body; Two types of LBs; Toxic mechanisms; Lewy neurites; … |
| 20240722_182524 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | PET aSyn vendor matrix (AC Immune / MODAG / University of Zurich / QST / Shenzhen / Merck / Mass Generic at Brigham) — Lead compound, Derivative, Structure, patient, Timeline, detects, in vitro Saturation binding affinity, IF, ARG, Preclinical Tox start; PET aSyn vendor matrix; Preclinical Tox (start) |
| 20240722_182528 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | PET aSyn vendor matrix tail (Animal Cold/Hot, Animal in vivo PET, ARG, Preclinical Tox 2-rat studies, FH Protocol Eval, Protocol B-safety, FH F/U + team note, Four αSyn isomers, Alzforum half-life note); PET aSyn vendor matrix (continued); Alzforum potential booster |
| 20240722_182532 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | PET aSyn vendor matrix (Takeda CS 20230427, AlzForum FOSO28, MJF supported, Method comparison Smith 2023, SPAL-T-06 vs C05-05, Round 2 compound), Takeda co-owner license agreements; PET aSyn — vendor matrix continued; SPAL-T-06 vs C05-05; Takeda is co-owner of this asset; co-owner block |
| 20240722_182535 | Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn | PET aSyn — QST Specified Clinical Trial planning (Operational lead, Funding MJF, Schedule, IND, Goal, Protocol, Process, Contract, Freedom to operate, GLP-Tox); QST Specified Clinical Trial — planning (PET aSyn vendor matrix continuation) |
| 20240722_182539 | Pipeline of GD & GBA-PD > Supplement > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn > Postmortem aSyn | QST PET aSyn — process / contract / freedom to operate / GLP-Tox 20230808 plan, 20230714 Biomarker FlytoAs, Postmortem aSyn opener; GLP-Tox; (20230714) 3. Biomarker FlytoAs; Postmortem aSyn; Uncertain Spans |
| 20240722_182542 | Pipeline of GD & GBA-PD > Supplement > Postmortem aSyn > Release > Safety for aSyn > KO of α-syn > Seed-Amplification Assay | Postmortem aSyn detailed staging table tail, Release of α-syn (sulfonylurea/SUR1 channel), Safety for aSyn / KO of α-syn (SNCA KO mice + Vilar 2018 + Markovich 2007), Seed-Amplification Assay (RT-QuIC) Materials/96 well/Real-time readout/Limitation/Advantage, vendor matrix (PPMI/Tichi/Penix/OPDC/Lema-Marambio/Caughey); Postmortem aSyn — staging table (continued); Release; Safety for aSyn; KO of α-syn; … |
| 20240722_182545 | Pipeline of GD & GBA-PD > Supplement > Safety for aSyn > KO of α-syn > Seed-Amplification Assay > Quantification | Seed-Amplification Assay (RT-QuIC) — vendor / study rows (Russo 2020 / Onia 2021 / Pankha 2014 / Arnold 2021 / Brown 2023 / Brookmeyer 2021 / Olucium 2023 / Groves 2018), Quantification opener (Kinetics readouts, Single-seed level, PrP-QuIC modeling, factors influencing lag time); Seed-Amplification Assay (RT-QuIC) — study rows; Quantification; Kinetics readouts; method (Quantification) |
| 20240722_182549 | Pipeline of GD & GBA-PD > Supplement > Seed-Amplification Assay > Quantification > Utility > Sources of aSyn | Quantification continued, end-point dilution + Calibration curve, application, Utility (Sidoroy 2023 Syn-target / RRK2-targeted / Aa-targeted), MJF workshop 20220421, Sources of aSyn (Cell/Brain/Recombinant/Synthetic + Aβ Figure 1); Quantification (continued); Utility; MJF workshop 20220421; Sources of aSyn |
| 20240722_182552 | Pipeline of GD & GBA-PD > Supplement > Sources of aSyn > Skin aSyn > Species > Native conformation > Summary aSyn species | Sources of aSyn detailed table (Recombinant / cell culture / Brain extract / Chemical synthetic with Method / pros / Product / parameter modelling rows), Skin aSyn (Syn-One test, Vasiliev 2018, Donadio 2024 #2752), Species / Native conformation, Primary aSyn species table (monomeric / tetramer / pSer129 / Misfolded / β-pleated sheet / Insoluble / Oligomeric / protofibril / amyloid-like fibril / Lewy bodies); Sources of aSyn — detail table; Skin aSyn; Species; a-syn primary conformation; … |
| 20240722_182556 | Pipeline of GD & GBA-PD > Supplement > Summary aSyn species > NDE > Fragments (Truncation) > Assay Truncation | Primary aSyn species table tail, BDD update 202305 N-terminal α-synuclein, NDE (TAK-341 IDP / ADx + Cooveohe collaborations), Analyt-NIA ELISA SG4, Fragments / Splice variation (C-terminal truncation 10-30%), Assay Truncation (LC-MS isoform characterization); Primary aSyn species — table tail (continued); (BDD monthly update 202305) — BDD - N-terminal α-synuclein (Cterminal); NDE (Neuronal-derived exosome); Analyt-NIA ELISA (SG4); … |
| 20240722_182559 | Pipeline of GD & GBA-PD > Supplement > Summary aSyn species > NDE > Fragments (Truncation) > Assay Truncation | Assay Truncation continued (BDD update 202404, Kahn 2024 #2973 LC/MS isoforms in cingulate cortex), SNCA truncation isoforms (-126/-112/-98 with theoretical MW/aa), Bluhm 2021 #2157 schematic protease cleavage map (trypsin/MMP-3/Calpain-1/Cathepsin D/Neurosin/casp1), Sorrentino 2020 schematic, binding site 102-130 abundance table; Assay Truncation (continued); SNCA truncation isoforms; (Bluhm, 2021 #2157); (4.1 binding site 102-130) — abundance table |
| 20240722_182602 | Pipeline of GD & GBA-PD > Supplement > NDE > Fragments (Truncation) > Assay Truncation > Structure of aSyn | Halia 2014 #2073 truncation table tail, Splice variation (4 αSyn transcripts SNCA-140/-126/-112/-98), Beyer 2008 Neurogenetics alignment, TAK-341 epitope on exon 5, Pathological Conversion + Pathological Aggregation cycle figure, Structure of aSyn opener, Brain Res 2012 1432:90 α-synuclein domain figure, 4q21.3-q22 chromosome diagram; (Halia, 2014 #2073) — truncation isoform table tail; Splice variation; Pathological Conversion → Pathological Aggregation cycle; Structure of aSyn; … |
| 20240722_182606 | Pipeline of GD & GBA-PD > Supplement > Assay Truncation > Structure of aSyn > Synapse and aSyn > TM for aSyn programs | Three major αsyn domains (N-terminal / NAC / C-terminal acidic tail), Synapse and aSyn (Calleri 2015 90% presynaptic deposits), TM for aSyn programs (Monomer / Pansson 2018 fibril CDMS, αSyn oligomer enrichment plan, paSyn / Fragments / LB / PD vs MSA / DLB SPAL? rows); Three major αsyn domains; Synapse and aSyn; TM (target modulation) for aSyn programs; PD vs MSA / DLB ? (SPAL?) |
| 20240722_182609 | Pipeline of GD & GBA-PD > Supplement > Synapse and aSyn > TM for aSyn programs > Turnover of aSyn > ATP13A2 (Park9) | TM for aSyn programs continued (TAK-341 in hippo / SNCA MEDI-1341 / SNCA p3 / How long?), Turnover of αSyn (Stefano 2018 #770 review with αSyn 240h half-life table by macroautophagy / cathepsin D / lysosomal pathways), ATP13A2 (Park9) opener (gene/structure, KRD, NCL, Heterozygous carriers, ATP13A2 in Lewy bodies); TM for aSyn programs (continued); Turnover of αSyn; ATP13A2 (Park9); NCL; … |
| 20240722_182613 | Pipeline of GD & GBA-PD > Supplement > ATP13A2 (Park9) > BBB / disruption / opener > BD > Process / BeyondBio > Biobank | ATP13A2 (Park9) MUA + Animal model + ATSURO MICRO + PXEAEAU Lysosomal protein degradation + SAL BAC + MPO score + Disruption of BBB + BBB disruption in PD + BBB opener Cordance + non-confidential CDA + BD/Process/BeyondBio + Biobank + PPMI; ATP13A2 (Park9) — MUA; Animal model; ATSURO MICRO; BUCITAL DIO; … |
| 20240722_182617 | Pipeline of GD & GBA-PD > Supplement > Process > BeyondBio > Biobank > MJF | PPMI Subjects/Available Data/Biospecimens, Shahn Rahmadhan + Por 20240228 Samantha notes, BioFiND, LRRK2 Cohort Consortium (LCC) Cross-sectional + Longitudinal + 23&Me Studies, S4 Systemic Syn Sampling Study (Chahine 2020 #1605), Cf SC12 antibody note, Nilo-PD opener; PPMI; BioFiND; Available Biospecimens and Data; LRRK2 Cohort Consortium (LCC); … |
| 20240722_182620 | Pipeline of GD & GBA-PD > Supplement > BeyondBio > Biobank > MJF > Netherlands Brain Bank | Nilo-PD continued (Cohort 1/2 + Available Data + Biospecimens), MJFF PPMI iPSC LINES, MJFF biobank contacts, 14 Types of Samples Available, Cohort Consortium ETBNRPP, tranSMART panel, Netherlands Brain Bank opener (autopsy procedures + paraffin embedded samples); Nilo-PD (continued); MJFF PPMI iPSC LINES; MJFF biobank — contacts; 14 Types of Samples Available; … |
| 20240722_182624 | Pipeline of GD & GBA-PD > Supplement > BeyondBio > Biobank > MJF > Netherlands Brain Bank | Netherlands Brain Bank tissue request continued (Sample transfer process / MTA / Transportation / cost per sample / IHC paraffin vs frozen / Molecular analysis / Location-Region-Analysis-Brain Amount table / Tony Wolinsky purchasing flow / NBB blood-cells correction / genetic testing / segregation in the family / pathogen testing / NLRP3 plan / AD co-pathologies / Braak stage classification opener); Netherlands Brain Bank — tissue request flow; Transportation; cost per sample; IHC paraffin preferred / frozen + Tissue; … |
| 20240722_182627 | Pipeline of GD & GBA-PD > Supplement > Biobank > MJF > Netherlands Brain Bank > Imperial College Brain Bank | Braak staging diagram tail (Thal 2002 + CERAD), Imperial College Brain Bank (Parkinson’s UK contacts + sample request + section types + tissue collections + materials + Jaewon QA), ~400 genotyped PD cases table opener; Braak staging diagram (continued); Imperial College Brain Bank; Controls definition; Section types; … |
| 20240722_182630 | Pipeline of GD & GBA-PD > Supplement > MJF > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks | Imperial College Brain Bank PD genotyping table tail, sample availability + USDA statement, Imperial College Brain Bank Ariba PO process, Other Biobanks (NCNP J-PPMI Niigata univ TMM Cohort Study); Imperial College Brain Bank — sample availability; Other Biobanks; J-PPMI (Juntendo Univ); Niigata univ — Postmortem brain PD aSyn fibril; … |
| 20240722_182634 | Pipeline of GD & GBA-PD > Supplement > MJF > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks | UK Brain Bank Network (NBB), BDR / NeuroChip / Camp dataset access table, NIH NeuroBiBank, NCRAD + EUFortuv MICAgou, PrecisionMed, BIOIVT hemoglobin, fibroblast vendors (NINOS / Cell Applications / Lonza / Lifeline / promogen / Sanjusbo / LEDBO / Cellbio / pmgenel), Biochain catalog, BioSEND, Novus Biologicals NB820-59177; UK Brain Bank Network (NBB); BDR access table; NIH NeuroBiBank; NCRAD (National Centralized Repository for Alzheimer’s Disease and Related Dementias); … |
| 20240722_182637 | Pipeline of GD & GBA-PD > Supplement > Netherlands Brain Bank > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan | Other Biobanks register continued (BIOIVT, vendors, Biochain, BioSEND, Novus Biologicals, ACCEGEN, Genomics England Banner Brain, NJ Brain Endowment Bank, NDRI, Neurobiobank Munich), Korean Open Government License KOGL Type 4, J-PPMI NCNP, Biobanks in Japan table; Other Biobanks register (continued); Novus Biologicals — NB820-59177 (continued); ACCEGEN; Genomics England Banner Brain; … |
| 20240722_182641 | Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan > BIOMARKER | Biobanks in Japan tail (Tsukuba1 + Kyoto-U Nagahama phase0), 20231009 Hooki Tsmurni Niigata univ, BWMVRINER NSTM BM Tracking (KPI) matrix, GBA Activity / GBM / GACer assay rows, CSF Sample (Sato) prototype, CSF & NDE row, ARM lysosomal marker discussion; Biobanks in Japan (continued); 20231009 Hooki Tsmurni Niigata univ; BWMVRINER NSTM BM Tracking (KPI); CSF Sample (Sato); … |
| 20240722_182644 | Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan > BIOMARKER | BIOMARKER tracker matrix continuation — lysosomal markers + aSyn / GlcSph / SCSF assay rows, Annapurna note, C8H CSF LCMS, Dr Margreith UMCS oligo aSyn discussion, MID/ELISA Parkin assay (cGAMP / pSer65-Ub), CSF Buffer 125 pg/mL row + Migdalisa Richards Ciegg patient sample notes; BIOMARKER tracker — lysosomal markers + aSyn; GlcSph (Sato); GlcSph & GalSph (Sato) — assay status; C8H CSF LCMS; … |
| 20240722_182704 | Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japan > BIOMARKER | BIOMARKER tracker continued — pSer65-Ub MJ assay (Atalee + SMC4Ps + Boston Bioscience LSBio antibody), MITOKININ NBB CSF, BoMM 240 NBB samples, NLM newsletter PhanoSwitch saliva-EV proteomics, Korean RDDDU/OCT decision note; BIOMARKER tracker (continued); pSer65-Ub MJ assay updates; pSer65-Ub assay sensitivity / quantitation; MITOKININ NBB CSF; … |
| 20240722_182708 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra | BIOMARKER tracker continued (Oxygen consumption + LC3 II), Stage / Date / Deliverables panel, BMx Platform / BPS / Feasibility / BFA / Technical / BTV / IVC / GPT / Tox / BFP stage matrix, BioOrchestra opener (B amyloid CD36 microglia, miR-485-3p, ELAV12 / Sckeckel 2016 #1591); BIOMARKER tracker (continued); Stage / Date / Deliverables (small panel); Wide tracker matrix; BioOrchestra (start) |
| 20240722_182711 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood | BioOrchestra ELAVL2 / miR-485-3p target table (continued), nELAVL bullet notes, Blood section opener (WBC / PBMC / plasma table, innate vs adaptive immunity, blood sample handling); ELAVL2 / miR-485-3p target table (continued); Blood; Uncertain Spans |
| 20240722_182715 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood | Blood sample table tail (Suitable for RT PCR? / transcriptomics), Genomics England sample-handling guidance, Plasma / Serum / PBMC collection workflows, Lifespan / structure opener (classical monocytes emerge first from marrow); Blood sample table (continued); Plasma; Serum; PBMC (and PLASMA); … |
| 20240722_182718 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Blood > PBMC > Vendors of PBMC | Cell EM diagram citation, Lysosome / Example / 없는 것 table, mitochondria & aSyn notes, Sample preparation and process, Thawing and resting, Culture of PBMC, Vendors of PBMC table opening; Vendors of PBMC; Uncertain Spans |
| 20240722_182722 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Braak Staging | Vendors prospective tail, Braak Staging table (1-6 / HindBrain → Neocortex), Dx prodromal narrative, Zheng 2019 arrival-time chart, Masuda-Suzukake α-syn fibrils diagram, Takeda Braak / Propagation slides; Braak Staging; Abnormal α-syn fibrils (intracerebral injection to SN); Braak Staging of Parkinson’s Disease (Takeda slide); Propagation of α-synuclein Pathology: Human (PD) (Takeda slide); … |
| 20240722_182725 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Braak Staging | Burke 2008 H&Y vs Braak Stage scatter plot, Calcium channels (Cav subtypes table), SN DA neurons / Isradipine / In PD notes, askIT / CDA email thread (start); Fig. 3; Fig. 2; Calcium; CDA / askIT email thread (start); … |
| 20240722_182728 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | CDA email thread tail, CEI / Companies CEI / Vesalius distinct clinical feature types, Ambagon Argo molecular-glue 14-3-3 client table, Brain / CSF detection table, Giusto 2021 14-3-3 review, Underwood 2021 PFF mice notes; CDA email thread (continued); CEI; Companies CEI; Uncertain Spans |
| 20240722_182732 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | Underwood 2713 PFF tail, Zhao/Dzamko/muda LRRK2 14-3-3 notes, Ambagon-Takeda aSyn R&Rs confidential, 14-3-3 isoform/YWHA table, Deal concept / R&R, Mayor (AC immune) program, Competitor list, aSyn PET, Jaewon’s Lucy Tx Q&A, Samrara Tx Triage, Individual report (T3D / Neuracle / Nuravax); Mayor = AC immune; Samrara; Individual report (start); Uncertain Spans |
| 20240722_182735 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | Companies CEI / Individual report (T3D, Neuracle, Nuravax, Escape Bio, Amsterdam Neuroscience, Muna Tx, GNS Healthcare, BlueRock, Genuv, Lysogene, Sunnybrook, Vincent / TMEM175, Annovis Bio, amimod, ADRx); Individual report; Uncertain Spans |
| 20240722_182738 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Companies CEI | Companies CEI / Individual report (continued): amimod hepatotox tail, ADRx tau, Nuravax follow-up, NeuroPn, Yumanity, Athira, Innomedica, Kyowa Kirin, BioVie NE3107, Logos Bio ADAD gene therapy / OGA, Creus CxCR7, Neuroinitiative Parkin activator, Tigen Minipig RD, Neurolixis NLX-112 / NLX-101 / NLX-204, Tx Nurr1:RXRa program (BRF110); Individual report (continued); Tx — Nurr1:RXRa program (BRF110); Uncertain Spans |
| 20240722_182742 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Summary CEI | Tx Nurr1:RXRa BRF110 program tail (TE / Neuroprotection / aSyn / neuroinflammation rows), Seelos / Herophilus / Myro Tx / AcureX / VesperBio / Priavoid / D&D Pharma (Neuraly), GLP-1R agonists clinical trials table, Summary CEI section opener; Tx — Nurr1:RXRa program (BRF110); Companies CEI; Summary CEI; Projects in DD/Partnering Discussions:; … |
| 20240722_182745 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Summary CEI | Summary CEI continued: Confidential stage opportunities, Opportunities recently sent for triage, Relook at past MONITOR/Decline, NeuroD Landscape Refresh, NeuroD Heat Map, 20220906 Triage live discussion (Cerevel / Neuron23 / Creus / Ionis / NLRP3 group / Transitions Bio / Wren / Fluidic / AC Immune / Blue Rock), Key Projects Rundown, Heat Map / Competitive Landscape, SE Core Team Meeting agenda; Confidential stage opportunities and upcoming evaluation meetings; Opportunities recently sent for triage:; Relook at past MONITOR/Decline triage decisions:; NeuroD Landscape Refresh:; … |
| 20240722_182749 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Summary CEI | Summary CEI continued: Key Projects Rundown / Heat Map / SE Core Team agenda recap, NeuroD SE Core Team Meeting (November 1, 2022) topics, JP Morgan Planning, Project Torchlight / Apex / Turing / Bon / Link rundown, Late Stage Scan / Prescouter, 21130 protein-degrader landscape (C4 / Plexium / Kymera / Neomorph / Wren / Anima Biotech), Meetings CEI / heat-map CEI sharepoint links; Key Projects Rundown; Heat Map / Competitive Landscape (recap); NeuroD SE Core Team Meeting; Topics; … |
| 20240722_182752 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Cerevance > Deliverables | Summary CEI tail (Anima Biotech / Hi Julia), Heatmap CEI / Landscape / Meetings CEI sharepoint links, Cell lines (Neuronal catecholaminergic / Non-catecholaminergic / Non-neuronal tables), Cerevance Datasite & Deliverables (Project Acorn / CVN424 GPR6 inverse agonist) review table; Heatmap CEI; Landscape; Meetings CEI; Cell lines; … |
| 20240722_182755 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > CEI > Cerevance > Team | Cerevance Pipeline (CVN424 / CVN766 / CVN293 / CD38 / KCNJ6 / GPR65), Current Portfolio Status: April 2022 timeline, Key worlds (evaluation / scientific confidence / Opportunity), Team table (function ↔ team member); Pipeline; Current Portfolio Status: April 2022; Key worlds; Team; … |
| 20240722_182758 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Circuits > Direct pathway | Cerevance Team table (full), Centrifuge / ultracentrifuge note (Olga), Ceri Davies / Christine Klein meeting block, Mitochondrial biomarkers mini-table, Circuits / Direct pathway (cortex → striatum → SNc / GPe / GPi/SNr / STN → thalamus diagrams); Team; Centrifuge; Ceri Davies; Christine Klein; … |
| 20240722_182802 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Circuits > Indirect pathway | Healthy / Parkinson’s disease comparison panels, Direct pathway PD data table (SNc / D1 MSNs / GPi&SNR / thalamus / Cortex), Indirect pathway data table (D2 MSNs / GPe / STN / GPi&SNR / thalamus), DBS / GAD note, Input / Output diagrams, PD / HD cause-direct-indirect-consequence table, In HD subsection (D2 MSN / D1 MSN), Mhtt synaptic notes, Hypokinetic Sx; Healthy vs Parkinson’s disease (panel labels); Direct pathway (continued); Indirect pathway; Pathway summary; … |
| 20240722_182805 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Dose selection/finding | Hypokinetic / Hyperkinetic Sx tail, Decision-making row, Clinical trial Examples of PD (SAD), MAD, Finding (study in the target population), Concomitant Medication, Dose finding / Dose ranging study, Dose selection/finding study; Clinical trial Examples of PD; SAD; MAD; nding (study in the target population); … |
| 20240722_182808 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Sample size calculation | C-Path SWEDD vs DAT-Deficient slide (Conrado 2018), Summary from below percentages, Description table (intervention-based suppression of disease progression), WATCH-PD sample-size narrative, 2017 Simuni Table 1, 2018 Marek Column A table, TAK-341 IDP / ePOC / GBA GT PRC1 / 20210122_RSLT_GBA GT v2_GP rows; Rate of Motor Decline in SWEDD and DAT-Deficient Subjects was Different - Statistically and Clinically (slide); Summary from below; 바람직한 description: x% (intervention-based) suppression (or reduction in) of disease progression (relative to placebo); Uncertain Spans |
| 20240722_182811 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dose finding > Delayed start design | GBA GT v2_GP sample-size tail, 20190423 Sclareol-NS imaging strategy 4-panel chart, Sample size calculation (proportion / Visions Pharmaceutical 2021 #1755 / Lundkya 2013), Innovative design / Interim analysis / β regression model / FDA-EMA principle, C-Path DAT Enrichment slide, Delayed start design (Liu-Seifert 2015 sketch), MEAN STRIATUM DAT vs AV133 table; DAT Enrichment allows ~24% Reduction of Trial Size to Detect a Disease modifying Drug Effect with 80% Power (slide); Delayed start design; MEAN STRIATUM DAT vs AV133; Uncertain Spans |
| 20240722_182815 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Prevalence | AV133 sample-size tail, Cognition / Cholinergic / Anatomy (basal forebrain BF corticopetal projection / PPN-LDTC / MVN / striatal cholinergic interneurons), Pathway PET enzyme table (ChAT → VAChT → AChE → SDHACU), CUMULATIVE PREVALENCE OF COGNITIVE AND PSYCHIATRIC DISORDERS OR TREATMENT IN PD (Variable / Baseline / Year 1-5); Cognition / Cholinergic; Anatomy; Pathway, PET; CUMULATIVE PREVALENCE OF COGNITIVE AND PSYCHIATRIC DISORDERS OR TREATMENT IN PD; … |
| 20240722_182818 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > vMRI | Cumulative prevalence summary slide (50-70% / 25% bullets), vMRI literature matrix (Burton / Ramirez-Ruiz / Xia / Melzer / Goldsby / Apostolova / Mak studies); CUMULATIVE PREVALENCE OF COGNITIVE AND PSYCHIATRIC DISORDERS OR TREATMENT IN PD; vMRI; Uncertain Spans |
| 20240722_182821 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Pathology | vMRI tail (Segura 2018 cortical thickness), Aβ NPT brain/CSF, dual-syndrome hypothesis (fronto-striatal vs cholinergic posterior), Imaging (Aβ in PD / Forrencys 2018 / Florencys 2016 postmortem), sMRI Definition (SBM / VBM / SbM / DBM), Lewy Body score (composite / clinical / SCORE / Table FC), Pathology section (Hall 2014 postmortem); Imaging; sMRI; Lewy Body score; Pathology; … |
| 20240722_182824 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Consortium | Pathology tail (basal forebrain / hippocampal cholinergic system / Frontal cortex / ChAT activity), Hellinger 2008 review postmortem note, Consortium (MOBILIZE-PD / Verily / Takeda Japan / Watch / IDEA-NeXT / AMP-PD), PPMI (Enrollment / LP / Genetics Consensus / Visit / DaTscan completeness), Operations Manuals & Specimen Processing Maps, Other PPMI Program Protocols, Data & Biospecimen Use Agreements; Consortium; PPMI (Parkinson’s Progressive Markers Initiative); Study Documentation; Operations Manuals and Specimen Processing Maps; … |
| 20240722_182827 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Consortium | PPMI Study Documentation / Operations Manuals overlap, Other PPMI Program Protocols, Data and Biospecimen Use Agreements and Policies, LBD (Aria 2020 #2728) sub-study, Innovative Medicines Initiative (CSF Acoustic Kit / Olink / Complement Luminex / Somalogic SomaScan 7K), EUbOPEN, PD BRAC access flow (NINDS BioSEND / Harvard Biomarkers Study / MJFF Cohorts BioFIND / DATATOP / FS-ZONE / LRRK2 / SURE-PD), MJFF Grant Portal opener (MJFF-019845 MC1 PET); Data and Biospecimen Use Agreements and Policies; Sub-Studies; LBD (Lewy Body Dementia); Innovative Medicines Initiative; … |
| 20240722_182830 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Contacts | MJFF Grant Portal block (Pre-Proposals / Coordinating Lead PI / Full Proposal Invitations), MJF imaging meeting along with MJFF, WORKSHOP 202111 day2 conference slide, Canada / PDGENeration / Stephenson 2019 / Rare Disease Data Registry of Japan / Dr. Takeda AMED contacts, ATCs (Contacts) table opener (Soon Chung / Riley Frilghity / Rae Estrella / Won Lee / Jaewon Lee / Jaya Rosen / Jeffrey Knight / Leonis Papakosta / Zach McQuade / Toro Tomimatsu); MJFF Grant Portal — Outcome Measures; Can you switch PI’s after submitting a Pre-Proposal?; What does it mean to be a Coordinating Lead Principal Investigator?; MJF imaging meeting along with MJFF; … |
| 20240722_182833 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > CSF | Rare Disease Data Registry tail / Dr. Takeda AMED tail, Contacts (extended), MTM Contact info, Cortellis Drug Discovery Intelligence (Sequence search BlastP/BlastN), CROs (오시리스 사 / KBio Health / ATECH / WA BIO), Cryofluorescence tomography (CFT) slide opener, CSF section opener (immunoassay volume notes / GICph); Contacts (continued); MTM Contact info; Cortellis; CROs; … |
| 20240722_182836 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > CSF Flow | CSF Flow / Blood contamination / Fluid compartments / Barriers in the brain; Blood contamination; CSF Flow; Fluid compartments in the brain; Barriers in the brain |
| 20240722_182839 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Human CSF sampling | Brain CSF illustrations / Barriers table overlap, Brain structure (ECF / parenchyma / ventricular system), CSF turnover (4×/day), SE as a Surrogate for Assessing CNS Exposure (Lamotrigine / Phenytoin / Tiagabine / Acelagon AUC matrix), Sources of CSF proteins, Antemortem vs postmortem (Subhash 2008), Human CSF sampling (lumbar puncture 15-20 mL / 30 mL maximum), Cisterna magna puncture vs Catheter implantation, rhesus macaque CSF (Clingerman 2010 #1819), Serial sampling opener; Brain structure; Turnover; SE as a Surrogate for Assessing CNS Exposure: An Industrial Perspective; Sources of CSF proteins; … |
| 20240722_182842 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Interferons > interferon-stimulated gene | Mouse CSF / Rat CSF serial sampling tables, Cytokines Classification (Interleukins / Chemokines / Interferons / TNF / Colony Stimulating / TGFβ), Interleukins (IL-1β / IL-6 / IL-9 NLRP3 narrative), Interferons (Type I / Type II / IFN-γ MHC class II), interferon-stimulated gene (ISG) MOA (JAK-STAT / IFNAR / ↑ ISG gene expression), Multiplex cytokine assay (Mouse / Rat / Human Luminex / Olink panels); Serial sampling — Examples; MOUSE CSF; Rat CSF; Cytokines; … |
| 20240722_182845 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Multiplex cytokine assay | Interferons / ISG overlap, Multiplex cytokine assay (R&D Systems Luminex 50uL / Proteome Profiler Rat XL / Olink 48 mouse panel / 96 mouse exploratory / 92 human / pricing / detectability), DBS section opener (Mid PD EARLYSTIM 2y f/u Schuepbach 2013 #1892); Multiplex cytokine assay; DBS |
| 20240722_182848 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Diagnosis of PD | Olink panels overlap, D&D Phamatech (NLY01 NCT04154072), DBS (EARLYSTIM Schuepbach 2013 + Indication / Side effects / Prognosis bullets), DDC (Aromatic L-amino acid decarboxylase): AADC enzyme / Keaton 2023 / Perera 2023 / Petlawski 2023 / Cieselska 2017 / 18F-L-DOPA PET (Calabria 2016), Diagnosis of PD (MDS criteria / Postuma 2017 / Geils’s criteria opener); D&D Phamatech; DBS; Indication; Side effects; … |
| 20240722_182851 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Digital Trials | DDC AADC overlap (Cieselska 2017 / 18F-L-DOPA / Why increase / Qs), Diagnosis of PD overlap, Stages of early PD overlap, Digital section opener (Lipsmeier 2018 PMID 29701258 / 6-month Phase 1b smartphone trial / APDM composite motor endpoint), Konectom Roche-Biogen partnership, Digital Trials APDM ML feature reduction (122 → 28 → 9 → Random Forest 25 features), WATCH-PD Takeda + Biogen + MJFF program, APDM walking-feature characteristic table opener (Ratio of peak power / spontaneous tremor detection); Digital; Lipsmeier et al. 2018, PMID 29701258 / Clinical P1; goal; Validation required; … |
| 20240722_182854 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Digital Trials | APDM ML / Lipsmeier 2022 / WATCH-PD overlap, APDM walking-feature characteristic (Tremor / Bradykinesia / Postural / Mobility / Speech), Timed walking / Stand and go / Postural sway / standing walk / cadence sub-tables, Issues block, MDS-UPDRS Items vs Subitems coverage matrix (Arm swing / Stance time / Cadence / Double support time / Turn duration), (Adams, 2022 #2373) Supplemental Table 2 (Wearable Sensoria / Smartphone / Smartwatch device-assessment matrix); APDM walking-feature characteristic; Issues; MDS-UPDRS Items vs Subitems coverage matrix; (Adams, 2022 #2373) Supplemental Table 2. Description and location of assessments conducted with the digital devices used in the study |
| 20240722_182857 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Digital Trials | Adams 2022 supplemental table tail, NCT06219629 LEARNS observational basket study, TAK071-2002 crossover trial, TAK994-2001 PK/safety phase 2 trial, TAK-341 IMED1341 MAD Apple Watch feasibility, NEA-FAST scope, Verily watch (google) JMO observational study, mObILiZe-D consortium / Bre-One uLIZE-D Apple Watch+McRoberts+Dynaport feasibility opener |
| 20240722_182900 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > Disease area TM strategy | WATCH-PD/Konektm overlap, SWO-001 Japan / CarefoOne Apple Watch ongoing rows, (Drowy, 2020 #1223) Comparison of drug pharmacotherapy survey table, Digital PD Summary (US/EU vs Japan studies), Disease area TM strategy (Mitochondria / Neurodegeneration / POC framework / Human sample / Disease modelling), Project relevance / Candidate BM / Assay development matrix (α-Syn CSF / α-Syn PET / α-Syn Retina / lysosomal markers / CSF p65-Ub / functional mitochondrial CSF BM / NAD+ 31P MRS imaging); (Drowy, 2020 #1223) Comparison of drug pharmacotherapy in Parkinson’s disease — Table 1; Digital PD / Summary; Disease area TM strategy; Uncertain Spans |
| 20240722_182904 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DLB vs PDD vs MSA | Disease area biomarker table tail (CSF p65-Ub / Functional mito CSF BM / imaging / α-syn / Lysosome rows), Omics resources (Silberring 2010 #1148), DJ-1 (Park7) block, DLB vs PDD vs MSA comparison table opener (Prevalence / Incidence / Onset / Life expectancy / Dementia / RBD / Visual hallucination / Parkinsonism / Autonomic Sx / Four core indicative diagnostic biomarkers / Supportive / Clinical Dx / DATscan / Mokette / Nocker reference table); Disease area TM strategy (continued); Omics; DJ-1 (Park7); DLB vs PDD vs MSA; … |
| 20240722_182907 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DLB vs PDD vs MSA | DLB vs PDD vs MSA imaging / pathology rows (VMAT PET / sMRI Burton-Borroni-Cohn / aSyn PET DWI Pellecchia / Synuclein-only inclusions Olivera 2021 / Aβ load Hepp 2018 / NFT / Brainstem-Limbic-neocortical / Chia 2021 GWAS / GBA mutations and MSA) |
| 20240722_182910 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Cholinergic > DNA damage | DLB vs PDD vs MSA tail (Aβ / NFT / GWAS / GBA / SNCA / CSF αsyn / Clinical trial), MSA agent registry (Lithium / Stem cell / Mesenex αSyn immunotx / Bicheron verepinstat), DNA damage section opener (definition / Causes / Type-Repair table opener / Consequence DDR / Major pathways of DNA repair table opener); DLB vs PDD vs MSA — Clinical trial implications; DNA damage; Causes; type; … |
| 20240722_182913 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Dopamine metabolites in PD | DNA repair tail (Homology-directed / Non-homologous / Microhomology-mediated / Direct reversal / Translesion synthesis), DNA damage in PD (Sariguchi 2021 #1782 γH3AX / DNA glycosylase upregulation / NTH-1 decline with age), MOA in PD (BER capacity / SSB intermediates), Dopamine system / Catecholamine pathway (L-DOPA → DA → DOPAC / 3-MT / HVA / MAO / COMT illustrations + 18F-DOPA tracer), Dopamine metabolites in PD opener (Beriheimer 1973 #1749 postmortem 39 PD; LeWitt 2011 #1782 DATATOP CSF); DNA damage in PD; MOA in PD; Dopamine system; Catecholamine pathway; … |
| 20240722_182916 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Summary of dopamine system | Dopamine metabolites in PD — CSF / blood / urine correlation rows (LeWitt 1992 / Stefani 2017 / Wichi 2021), Anderson 2017 DA-HVA L-DOPA narrative, Dormant dopaminergic neurons (Heo 2020 astrocytic GABA / optogenetic SNpc rescue), Summary of dopamine system table opener (Hurley 2010 #1270 J. Boy 2000 Lee 18F-DOPA AADC PET / 11C-DTBZ / 11C-MP / Seeman-Niznik 1990 / Hisahara-Shimohama 2011); Dopamine metabolites in PD (continued); Dormant dopaminergic neurons; Summary of dopamine system |
| 20240722_182919 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Dopa Imaging | Microdialysis tail (Wegrzynowicz 2019), Nigrosomes (dopaminergic) neurons in SNpc (postmortem 98% loss in nigrosome-1), brain MRI swallow-tail panels, Dopa Imaging — dopamine synthesis capacity (11C-LDOPA / 18F-DOPA / Brooks / Snow / Hunhoff-Detto / Sossi / Morley / Adams / Lee / Oehme / Nagatsu narratives), dopamine transporter Imaging opener; Nigrosomes (dopaminergic) neurons in SNpc; Dopa Imaging — dopamine synthesis capacity; Dopamine transporter Imaging |
| 20240722_182922 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Imaging > DATscan in PD | DAT imaging products (PET / SPECT tracers / sensitivity / normal reference values), DATscan analogue references, DATscan in PD findings (caudate / putamen / striatum percent reduction; UPDRS correlation), Datscan and CSF NfL effect size, Datscan progression in PD opener (Simuni 2018 #2272 PPMI 대략 인 10%/year); DAT imaging products; DATscan in PD; Datscan and CSF NfL effect size; Datscan progression in PD; … |
| 20240722_182926 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Imaging > DATscan in PD | Datscan progression in PD (Simuni 2018 #2272 Table 5 baseline-Month 6/12/24/48; Table 7s Year 1/Year 4 percent change), Arthur volcano AD-PD database mining longitudinal DaT trajectories + power analysis evidence panels, Kim 2018 review Table 1 Previous Longitudinal Studies of DAT Imaging in PD Patients (Marek/Seibyl references), Correlation between Datscan & MDS-UPDRS opener (TABLE 4B Spearman correlations); Datscan progression in PD (continued); Arthur volcano AD-PD (Simen AAA 18-Apr-2018, S pots); (Jpod review used by chajn Kim 2018 #2018); Correlation between Datscan & MDS-UPDRS; … |
| 20240722_182929 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine transporter Imaging > Rodent Dopamine transporter | TABLE 4C / 4A correlation tables (Year 0/1/2/4 Spearman MDS-UPDRS × DATSCAN SBR), 6Mo vs UPDRS III / 4Y vs UPDRS III longitudinal rows (Tribais 2019 / Toiraj 2022), Correlation between Datscan & histologic markers (Doplowski 2013 #1067 mice TH/FA/DAT/striatal-fiber correlations), Correlation between Datscan & SN volume (Isaacs 2016 #1065 cross sectional), Rodent Dopamine transporter imaging — Summary of imaging centers (QST / Sekirai Medical / CIIA at Kawasaki / Medi-physics / Hamamatsu Photonics), CBigD studies opener; Longitudinal correlation between Datscan and UPDRS; Correlation between Datscan & histologic markers; Correlation between Datscan & SN volume; Rodent Dopamine transporter imaging; … |
| 20240722_182932 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neuromelanin pigment | Rodent imaging centers overlap, KBigD studies (KH Park 2020 18F-PR-PE2I MPTP-mouse / Js 2019 11C-PE2I 6-OHDA-rat / AAV SNCA-rat), Charles Rivers studies, SWEDD section (Marek 2018 #1283 PD PROTOpos), Neuromelanin pigment definition / Expression / DISTRIBUTION / Synthesis pathway diagram (DA → DA-quinones → DA-protein adducts → Pheomelanin → Eumelanin / Neuromelanin organelle); SWEDD; PD PROTOpos (Marek, 2018 #1283); Neuromelanin pigment; definition; … |
| 20240722_182935 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neuromelanin-MRI | Neuromelanin pigment biochemistry (Zecca review caption: NM-pigment biosynthesis & NM-containing organelle formation in human SN), Function (chelate iron / pigmented neurons vs TH correlation, Mor 2008 #1643), Rodent vs NHP, Neuromelanin-MRI section opener (Principle Sulzer 2018 #1597 / Iron in non-pigmented cells / SN pars reticulata, globus pallidus, caudate nucleus), METHODS (T1-weighted FSE / voxelwise NM-MRI / test-retest), Cassidy 2019 #1595 validation studies opener (NM-MRI vs neuromelanin tissue concentration / dopamine release / neural activity / clinical severity); Function; Rodent; Neuromelanin-MRI; Principle; … |
| 20240722_182938 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Dopamine system > Neuromelanin-MRI | NM-MRI validation table tail (Cassidy / Isaias / Ito), Longitudinal NM-MRI in PD (Cristian Salinas 20220625 commentary; Wirth 2022 #2071 Saljas cohort 140+97; vsNMc / disNMc / vsNMs annualized decay rates, UPDRS-III correlation), 79 early PD vs 32 HV cohort with manual SN segmentation, Dopamine Receptor imaging section opener (Booth 2015 #1745 raclopride PET / Bezard 2001 #1748); Longitudinal; Cristian Salinas (20220625); Dopamine Receptor imaging |
| 20240722_182941 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability | 79 early PD vs 32 HV cohort tail (cleaner copy at 20240722_182938), Dopamine Receptor Imaging continued (Booth 2015 #1745 raclopride PET / Bezard 2001 #1748 MPSP Monkey ABL plots), Druggability section opener (Lipophilicity definition / CNS penetration formulas / Kpuu values for paracetamol / HDACA / MOC950 / NLRP3 inhibitor / NoeITherm / AC immune compounds / selinexor; Rat Brain/Plasma Ratio bar chart); Dopamine Receptor Imaging (continued); Druggability |
| 20240722_182944 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI | Druggability; DWI VS DTI; Uncertain Spans |
| 20240722_182947 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI > Dyskinesia > Clinical presentation of Dyskinesia in PD > MOA of Dyskinesia | Druggability (continued tail); DWI VS DTI; Dyskinesia; Clinical presentation of Dyskinesia in PD; MOA of Dyskinesia; … |
| 20240722_182950 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI > Dyskinesia > Clinical presentation of Dyskinesia in PD > MOA of Dyskinesia > Outcome Measures Dyskinesia > Animal models of Dyskinesia > Pipeline of Dyskinesia | Dyskinesia; Clinical presentation of Dyskinesia in PD; MOA of Dyskinesia; Outcome Measures Dyskinesia; Animal models of Dyskinesia; … |
| 20240722_182953 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Druggability > DWI vs DTI > Dyskinesia > Pipeline of Dyskinesia > EEG > Bands > EEG in PD | Pipeline of Dyskinesia (continued); EEG; Bands; EEG in PD; Uncertain Spans |
| 20240722_182956 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > Bands > EEG in PD > Limitations > Sleep EEG > Effect size | EEG in PD (continued); Limitations; Sleep EEG; Effect size; Uncertain Spans |
| 20240722_182959 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > EEG in PD > Limitations > Sleep EEG > Effect size | Sleep EEG (continued); Effect size (continued); post-hoc; NLRP3 (or ASC) vs TH; correlation / Exact test; … |
| 20240722_183002 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > EEG > Effect size > Efficacy modelling > Electrophysiology > Anatomy of a neuron > Methods | Correlation / Exact test (continued); Efficacy modelling; Electrophysiology; Anatomy of a neuron; Methods; … |
| 20240722_183006 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Electrophysiology > Anatomy of a neuron > Methods > Resting potential (Inactive state) > Process | Electrophysiology; Anatomy of a neuron; Methods; Resting potential (Inactive state); Process; … |
| 20240722_183009 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Electrophysiology > Process > voltage-dependent ion channels > ERB > Endoplasmic Reticulum (ER) > 4 Exosome | Resting potential (Inactive state); Process; voltage-dependent ion channels; ERB; Endoplasmic Reticulum (ER); … |
| 20240722_183012 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Endoplasmic Reticulum (ER) > 4 Exosome > ConsoRCC > Example > 4 NDE > neuronal exosome enrichment procedure > Oligodendrocyte-derived exosome | Endoplasmic Reticulum (ER); Exosome; function; Limitation of exosome; Process; … |
| 20240722_183015 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Oligodendrocyte-derived exosome > Eye > Fibroblast > Cell model system for CNS? > GABA > Further readings > GABA imaging > review (Magrinelli, 2016 #1063) | Oligodendrocyte-derived exosome (continued); Eye; Fibroblast; Cell model system for CNS?; GABA; … |
| 20240722_183018 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GABA imaging > Gait > 4 Gait > Assessment of Gait > Galectin-3 > GCS inhibitor | GABA (continued); Further readings; GABA imaging; Gait; Assessment of Gait; … |
| 20240722_183021 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Gladstone Institute > Glutamate > Imaging > Goals > FY22 | Gladstone Institute; Glutamate Imaging; Goals; FY22; Experimental Medicine – KPIs for 2022; … |
| 20240722_183024 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Goals > FY22 > GWAS > Modifiers > Summary | GWAS; Modifiers; Summary; Uncertain Spans |
| 20240722_183028 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GWAS > Modifiers > Summary > LSD genes | LSD genes and variants in the IPDGC cohort; Uncertain Spans |
| 20240722_183031 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GWAS > Summary > LSD genes > GPR37 > Glossary > H&Y (Hoehn and Yahr) | LSD genes and variants in the IPDGC cohort; GPR37; Target; Glossary; H&Y (Hoehn and Yahr); … |
| 20240722_183034 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > GPR37 > Glossary > H&Y (Hoehn and Yahr) | GPR37; Target; Glossary; H&Y (Hoehn and Yahr); Uncertain Spans |
| 20240722_183037 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > H&Y (Hoehn and Yahr) > HA-tag > Hearing loss | HA-tag; Hearing loss; Nigrosome1 MRI; Nigrosome1 MRI; Uncertain Spans |
| 20240722_183040 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Hearing loss > Heuron > Hirozane, Yoshihiko > HR Performance Review (including 360) | Heuron; Hirozane, Yoshihiko; HR Performance Review (including 360); Human Biological Samples; Uncertain Spans |
| 20240722_183044 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > HR Performance Review (including 360) > Human Biological Samples > Imaging > PET | Human Biological Samples; Imaging; PET; Immunity; Uncertain Spans |
| 20240722_183047 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Immunity > Autoimmunity (Autoantibody) > Evidence > ImmunoPET > Imnewrun | Immunity; Autoimmunity (Autoantibody); Evidence; ImmunoPET; Imnewrun; … |
| 20240722_183050 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammation > ALS > aSyn (therapeutic) antibody > Comorbidity | aSyn (therapeutic) antibody; Comorbidity; Summary (sento M); Uncertain Spans |
| 20240722_183055 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Comorbidity > Signals > Inflammasome > In vitro model of neuroinflammation | Signals; Inflammasome; In vitro model of neuroinflammation; Uncertain Spans |
| 20240722_183058 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro model of neuroinflammation > Imaging neuroinflammation | Imaging neuroinflammation; Uncertain Spans |
| 20240722_183101 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro model of neuroinflammation > Imaging neuroinflammation | Uncertain Spans |
| 20240722_183115 | Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra > Inflammasome > In vitro model of neuroinflammation > Imaging neuroinflammation > Structure of microglia > Phenotypes of microglia > Markers of microglia | Markers of microglia; Priming of MG; Receptors on microglia; Uncertain Spans |